Arvinas doses first patient in Phase 1/2 trial of HPK1 degrader ARV-6723 in advanced solid tumors

• Arvinas dosed the first patient in a Phase 1/2 trial of ARV-6723 for advanced solid tumors.
• No clinical results have been presented; the study will generate initial safety, drug-behavior, and early antitumor readouts.
• Program expands Arvinas into immuno-oncology with an oral PROTAC designed to remove HPK1, a brake on immune activation.
• Trial tests ARV-6723 alone, then with pembrolizumab, targeting patients previously treated with checkpoint inhibitors lacking standard options.
• Preclinical work showed immune activation and tumor-control signals, including in models resistant to anti-PD-1 therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arvinas Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280700PRIMZONEFULLFEED9834349) on September 28, 2026, and is solely responsible for the information contained therein.